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Abstract 
It is well known that the presence of end-stage liver disease increases the risk of developing 
hepatocellular carcinoma (HCC). Liver transplantation (LT) for patients within the Milan crite-
ria has become a standard treatment for HCC in most developed centers worldwide. Howev-
er, a major cause of death in cirrhotic patients with HCC after transplantation is tumor recur-
rence, including peritoneal recurrences, which develops rarely but presents a significant 
problem with regard to their management. Our experience includes two cases with HCC 
within the Milan criteria of peritoneal recurrences after living donor LT. Both patients had 
interventions for HCC in their medical history before LT, and we propose that these might 
have been a possible cause of the HCC peritoneal recurrence. © 2015 S. Karger AG, Basel 
Introduction 
Several lines of evidence indicate that the presence of end-stage liver disease increases 
the risk of developing hepatocellular carcinoma (HCC). The prevalence of cirrhosis in pa-
tients with HCC is about 80–90% [1]. Since HCC is the third leading cause of cancer-related 
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death and one of the leading causes of death among patients with liver cirrhosis [2], screen-
ing for HCC in high-risk populations, especially liver transplantation (LT) candidates, has 
been recognized as a rational procedure. 
Liver resection for HCC is possible only in selected cases due to the high incidence of 
morbidity and mortality in patients with cirrhosis and elevated portal pressure. LT for HCC 
has been determined to be a viable option for treatment since Mazzaferro et al. [3] reported 
their landmark study that presented the criteria which became known as the Milan criteria. 
They showed that when transplantation was restricted to patients with early HCC (radiolog-
ically defined as a single lesion ≤5 cm, up to three separate lesions, none >3 cm, no evidence 
of gross vascular invasion and no regional nodal or distant metastases), a 4-year survival 
could be achieved for 75% of patients. These outcomes were similar to the expected survival 
rates for patients undergoing transplantation for cirrhosis without HCC. Later, several cen-
ters presented and analyzed their results of LT for patients with HCC in excess of the Milan 
criteria [4–6]. LT from cadaveric or living related donors has now become a common treat-
ment for patients with HCC in most developed centers worldwide. 
The limited availability of donor organs is a general problem in transplantation. While 
awaiting a donor organ, patients with HCC may be excluded from the ‘waiting list’ due to 
tumor progression. Locoregional therapy (LRT), such percutaneous ethanol injection, radio-
frequency ablation (RFA), transarterial embolization (TAE), transarterial chemoemboliza-
tion (TACE), stereotactic radiotherapy and radioembolization, was developed to prevent 
tumor progression until a suitable donor organ became available [7]. This type of therapy is 
often referred to as a ‘bridging’ treatment; however, there may also be oncological benefits 
of locoregional action, which indicates that these methods should be considered for use be-
yond the ‘bridge’ to transplantation in wait-listed patients. Therefore, the practice of treating 
HCC patients with LRT has also become a standard procedure before LT in most centers. 
However, peritoneal recurrences of HCC are uncommon, especially in patients who have 
undergone LT. We experienced the cases of two patients with HCC peritoneal recurrence, 
occurring 19 and 32 months after LT, respectively, and herein describe these cases and pro-
vide a review of the literature. 
Case Reports 
Between August 1997 and September 2014, 74 out of 210 recipients underwent living 
donor LT (LDLT) at the Department of Surgery of Nagasaki University Hospital for HCC eval-
uated by ultrasound, multispiral computed tomography and/or gadolinium ethoxybenzyl 
diethylenetriamine pentaacetic acid contrasted magnetic resonance imaging (Gd-EOB-DTPA 
MRI). Most of the patients were accepted for LDLT within the Milan criteria. 
The HCC recurrence rate in this series was 5.4%, meaning that only four of the 74 pa-
tients developed a recurrence of HCC after transplantation since we strictly followed the 
Milan criteria. Among them, two recipients had typical types of recurrences: one patient had 
recurrence in the liver and another had recurrence in the lung and liver. These two patients 
are not presented in the current study. The cases of the other two patients with peritoneal 
recurrence of HCC are presented below. 
Case 1 
A 52-year-old male patient had been diagnosed with liver cirrhosis due to HBV infection 
in 1980 and had been without regular follow-up due to lack of desire on his part. In 2008, he 
was diagnosed with three nodules of HCC in S4 and S5, the largest being 35 mm in diameter 
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(fig. 1a). Two months after these findings, the patient had rupture of the HCC nodule in S5 
and received urgent TAE for hemostasis (fig. 1b). He underwent LDLT 3 months after the 
episode of ruptured HCC (fig. 2a, b), with a Child-Turcotte-Pugh (CTP) class of C (10 points), 
a model of end-stage liver disease (MELD) score of 10 points, and also had HCC within the 
Milan criteria (fig. 2c, d). The tumor marker levels before transplantation showed an in-
crease in the PIVKA II level up to 423 mAU/ml, with a normal AFP level of 7.5 ng/dl. The 
patient was also treated following the general clinical and immunosuppressive protocol. 
Peritoneal dissemination was diagnosed in this patient 32 months after LDLT (fig. 3). He 
started to receive adjuvant therapy with sorafenib 400 mg without evident benefit, then 
after 1 month of this treatment was changed for to tegafur and uracil 400 mg, but after 
another 1 month this was also stopped due to lack of efficacy. After 6 months, the patient 
developed strong intra-abdominal pain, probably connected with the dissemination of 
the peritoneal tumor, and received palliative therapy. He died due to the progression of dis-
ease 70 months after transplantation. Maintenance immunosuppressive therapy was under 
tacrolimus with a trough level of 3–5 ng/μl without any signs of rejection. This patient was 
the only one who had ruptured HCC before LDLT in our series. 
Case 2 
A 62-year-old male patient with liver cirrhosis due to HCV infection since 1993 was 
found to have HCC in 2003 and underwent caudate lobe resection. After surgery, he received 
antiviral therapy, with a sustained virological response to antiviral therapy by interferon 
plus ribavirin. Four months after the liver resection the patient was found to have HCC re-
currence in the liver, and during the next 3 years, he consequentially received several 
TAE/TACE procedures for HCC in S2, S4 and S7, percutaneous ethanol injection for HCC in 
S7 and RFA for HCC in S2, with good clinical and roentgenological outcomes. 
Thirty-eight months after the initial finding of HCC, the patient underwent LDLT from 
his daughter, using a left lobe graft, and his treatment followed the general clinical protocol 
of the center, including immunosuppressive therapy. A few days before transplantation, 
the patient’s prognostic criteria presented with CTP class C (10 points), a MELD score of 
10 points and HCC within the Milan criteria. The tumor marker levels were normal: AFP 
1.9 ng/dl and PIVKA II 24 mAU/ml. Histopathological study of the explanted liver showed no 
evidence of malignancy. 
However, with elevation of AFP 19 months after LT, a single nodule of peritoneal tumor 
in the pelvic cavity was observed under PET/CT. Within 1 month the patient underwent 
peritoneal tumor resection, and histopathological investigation of the tumor revealed mod-
erately differentiated HCC. After 3 months, the patient was accepted for adjuvant therapy 
with sorafenib 400 mg, but at the same time, he was observed to have recurrence of the pel-
vic tumor, with invasion in the rectum, and it was noted that he also had liver recurrence. 
TACE was performed for both the pelvis and liver tumors, and thereafter the patient was 
supported with palliative treatment. After about 1 month of this treatment, the patient asked 
to be discharged so he could go home, where he died within 3 months. Overall, the patient 
survived 46 months after LT. Maintenance immunosuppressive therapy was under cyclo-
sporine with the trough level of 50–100 ng/μl without any signs of rejection. This case was 
partly reported in our previous publication [8]. 
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Discussion 
Belghiti and Fuks [9] consider LT to be the most popular therapeutic option for HCC, be-
cause hepatectomy removes all detectable and undetectable tumor nodules and preneo-
plastic lesions, as well as simultaneously treating the underlying cirrhosis and preventing its 
distant complications. However, a major cause of death in cirrhotic patients with HCC after 
transplantation is tumor recurrence, which developed in 3–26% of cases [10–12]. Avoidance 
of recurrence is currently not possible due to the lack of established adjuvant therapies; 
therefore, only adequate patient selection and preoperative management are used to ensure 
acceptable recurrence rates for most centers, achieving excellent survival after LT. Chemo-
therapy for HCC has no proven benefit [13, 14]. On the other side, the rate of HCC recurrence 
after LT is lower than that after liver resection or any other type of treatment, which may be 
up to 80% [15–17]. 
Peritoneal recurrences of HCC are uncommon [18]. The risk factors after liver resection 
(tumor size >50 mm, presence of microvascular invasion, bile duct invasion, positive re-
section margins) were proposed in a study presented by Kow et al. [19], which included 
36 patients with peritoneal recurrence of HCC among a total 1,222 cases who underwent 
liver resection. The authors also consider peritoneal metastases as an incurable terminal 
disease rarely suitable for surgical resection. Nakayama et al. [20] presented six cases ob-
served and treated in one center without LT, and several single case reports of peritoneal 
recurrences of HCC in patients treated without LT have been published worldwide. 
Peritoneal recurrences of HCC after LT are rare. The largest study presented in English 
describes only two cases of peritoneal recurrence among 685 transplanted patients, includ-
ing 202 with HCC [21]. This may demonstrate another benefit of LT for HCC management 
compared to liver resection or treatments. Tumor dissemination due to HCC rupture could 
be a possible mechanism underlying the distant tumor recurrence in our second case. A few 
case reports have described peritoneal metastasis after ruptured HCC. Chow et al. [22] de-
scribed their case of peritoneal tumor implantation after ruptured HCC, concluding that such 
recurrence may occur months to years after the initial presentation. Therefore, indication of 
LT after ruptured HCC should be carefully evaluated including staging laparoscopy. Ablative 
LRT techniques, including RFA and TACE, are used to promote tumor necrosis to control the 
progression of HCC. However, the potential impact of aggressive LRT on HCC recurrence, 
especially in distant sites, is still unclear and should be discussed including our previous 
study [8]. With regard to other possible predictors of distant recurrence of HCC, there is a 
consensus on the negative impact of pharmacological immunosuppression on the recurrence 
of HCC [23, 24]. Welker et al. [25] showed that lower levels of immunosuppressive agents 
are associated with a lower risk for HCC recurrence. 
In conclusion, we propose that HCC peritoneal recurrence is a rare complication for pa-
tients after LT, but that it can appear, especially when a patient has any background factors 
that might lead to recurrence before LT, such as ruptured HCC or LRT for HCC tumors. We 
have experienced two such cases, both of whom underwent LT within the Milan criteria. Due 
to disappointing outcomes of chemotherapy for HCC, it may be necessary to establish a 
screening program for patients who have a ruptured HCC or have received LRT before LT. 
Disclosure Statement 
The authors have no conflict of interest associated with this paper. 
33 
Case Rep Gastroenterol 2015;9:29–35 
DOI: 10.1159/000375117 © 2015 S. Karger AG, Basel 
www.karger.com/crg 
Sadykov et al.: Peritoneal Recurrence of Initially Controlled Hepatocellular Carcinoma 
after Living Donor Liver Transplantation 
References 
1 Fattovich G, Stroffolini T, Zagni I, et al: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. 
Gastroenterology 2004;127(5 suppl 1):S35–S50. 
2 El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142: 
1264–1273. 
3 Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular 
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699. 
4 Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: comparison of the 
proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 
2002;8:765–774. 
5 Shetty K, Timmins K, Brensinger MS, et al: Liver transplantation for hepatocellular carcinoma: validation of 
present selection criteria in predicting outcome. Liver Transpl 2004;10:911–918. 
6 Roayaie K, Feng S: Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? 
Liver Transpl 2007;13(11 suppl 2):S36–S43. 
7 Galuppo R, McCall A, Gedaly R: The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol 
2013;2013:419302. 
8 Eguchi S, Hidaka M, Tomonaga T, et al: Actual therapeutic efficacy of pre-transplant treatment on 
hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. 
J Gastroenterol 2009;44:624–629. 
9 Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012;1: 
71–82. 
10 Regalia E, Fassati LR, Valente U, et al: Pattern and management of recurrent hepatocellular carcinoma after 
liver transplantation. J Hepatobiliary Pancreat Surg 1998;5:29–34. 
11 Grasso A, Stigliano R, Morisco F, et al: Liver transplantation and recurrent hepatocellular carcinoma: 
predictive value of nodule size in a retrospective and explant study. Transplantation 2006;81:1532–1541. 
12 Sotiropoulos GC, Molmenti EP, Lösch C, et al: Meta-analysis of tumor recurrence after liver transplantation 
for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007;12:527–534. 
13 Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al: Does additional doxorubicin chemotherapy improve 
outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 
2005;5:788–794. 
14 Söderdahl G, Bäckman L, Isoniemi H, et al: A prospective, randomized, multi-centre trial of systemic 
adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular 
carcinoma. Transpl Int 2006;19:288–294. 
15 Lang H, Sotiropoulos GC, Brokalaki EI, et al: Survival and recurrence rates after resection for hepatocellular 
carcinoma in noncirrhotic livers. J Am Coll Surg 2007;205:27–36. 
16 Bismuth H, Chiche L, Adam R, et al: Liver resection versus transplantation for hepatocellular carcinoma in 
cirrhotic patients. Ann Surg 1993;218:145–151. 
17 Itamoto T, Nakahara H, Amano H, et al: Repeat hepatectomy for recurrent hepatocellular carcinoma. 
Surgery 2007;141:589–597. 
18 Yeh CN, Chen MF: Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: 
risk factors and prognostic analysis. World J Surg 2004;28:382–386. 
19 Kow AWC, Kwon CHD, Song S, et al: Risk factors of peritoneal recurrence and outcome of resected 
peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1,222 cases of 
hepatectomy in a tertiary institution. Ann Surg Oncol 2012;19:2246–2255. 
20 Nakayama H, Takayama T, Makuuchi M, et al: Resection of peritoneal metastases from hepatocellular 
carcinoma. Hepatogastroenterology 1999;46:1049–1052. 
21 Escartin A, Sapisochin G, Bilbao, et al: Recurrence of hepatocellular carcinoma after liver transplantation. 
Transplant Proc 2007;39:2308–2310. 
22 Chow KC, Tang CN, Lai EC, Li MK: Curative treatment for recurrent tumor implantation after ruptured 
hepatocellular carcinoma. Hong Kong Med J 2013;19:82–84. 
23 Vivarelli M, Cucchetti A, La Barba G, et al: Liver transplantation for hepatocellular carcinoma under 
calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857–862. 
24 Chinnakotla S, Davis GL, Vasani S, et al: Impact of sirolimus on the recurrence of hepatocellular carcinoma 
after liver transplantation. Liver Transpl 2009;15:1834–1842. 
25 Welker MW, Bechstein WO, Zeuzem S, et al: Recurrent hepatocellular carcinoma after liver transplantation – 
an emerging clinical challenge. Transpl Int 2013;26:109–118. 
34 
Case Rep Gastroenterol 2015;9:29–35 
DOI: 10.1159/000375117 © 2015 S. Karger AG, Basel 
www.karger.com/crg 
Sadykov et al.: Peritoneal Recurrence of Initially Controlled Hepatocellular Carcinoma 
after Living Donor Liver Transplantation 
Fig. 1. A well-defined nodule (4.0 × 3.8 cm) of HCC in S5 of the liver (case 1). a Before it ruptured (arrow). 
b After it ruptured and embolized (arrow). 
Fig. 2. a No peritoneal dissemination at laparotomy. b Left lobe graft. c Explanted liver with HCC (arrow). 
d Cross-section of explanted liver with HCC (arrow). 
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Fig. 3. The peritoneal recurrence (5.6 × 5.3 cm) found by a CT scan (case 1). 
